<DOC>
	<DOC>NCT01911637</DOC>
	<brief_summary>VBY-036 may treat or prevent nerve pain. This study aims to find the highest safe and tolerable single dose of VBY-036 in healthy volunteers. Volunteers are randomly selected to receive one dose of either a placebo or VBY-036 (10, 30, 100, 300, 600 or 900 mg).</brief_summary>
	<brief_title>Safety Study of Single Oral Doses of VBY-036 in Healthy Volunteers (VBY036P1A)</brief_title>
	<detailed_description>Detailed description is noted in Brief Summary.</detailed_description>
	<criteria>Male or female, 1860 years old Screening body mass index between 1832 kg/m2 Good health, no clinically significant findings in medical history, 12lead ECG, &amp; vital signs; Clinical lab evaluations (Chem panel [fasted at least 8 hrs], CBC, HbA1c &amp; UA in reference range for test lab (unless deemed not clinically significant); Negative test for drugs of abuse at Screening &amp; at Checkin (includes alcohol); Negative hepatitis, HIV &amp; TB screens; Females nonpregnant, nonlactating, &amp; either postmenopausal for at least 1 year, surgically sterile for at least 90 days prior to Checkin, or agree to use from the time of consent until 90 days after Study Completion an effective form of contraception. For all females, a pregnancy test result must be negative at Screening &amp; Checkin. Males will be sterile or agree to use from Checkin until 90 days following discharge an effective method of contraception. Able to comprehend &amp; willing to sign Informed Consent Form Females pregnant or nursing, or childbearing potential but unwilling to use contraception. History of renal or hepatic impairment; stomach or intestinal surgery or resection, malabsorption syndrome, cholecystectomy, or gastrointestinal dysfunction that would alter absorption &amp;/or excretion of orally administered drugs (appendectomy or hernia repair allowed); Anemia (hemoglobin &lt;11.5 g/dL for females; &lt; 13 g/dL for males) or blood donation within 8 weeks of Checkin; Plasma donation within 4 weeks of Checkin; History of alcoholism or drug addiction within 6 months to Checkin; Use of drugs of abuse or prescription drugs for recreational use 6 months prior to Checkin; Use of any tobaccocontaining or nicotinecontaining products 6 months prior to Checkin &amp; during study; Participation in another drug trial 30 days of Checkin (within 8 weeks if previous investigational drug has immunomodulary effects, other than cathepsin S inhibition); History or clinical manifestations of metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, urological, neurological, or psychiatric disorders History of hypersensitivity or allergies to any drug compound History or presence of abnormal ECG Laboratory abnormality deemed clinically significant; Use of or inability to discontinue any prescription medications/products 14 days prior to Checkin &amp; during study; Use of certain overthecounter, nonprescription preparations are permitted up to 3 days before first dose; Use of alcoholcontaining, grapefruitcontaining, star fruit containing foods or beverages or "energy drinks" 72 hours to Checkin &amp; during study; Poor peripheral venous access; Receipt of blood products 6 months to Checkin Subjects with history of Gilbert's Syndrome; Strenuous activities 48 hours before receiving experimental or placebo comparator Illness 5 days to drug administration Any acute or chronic condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Subjects</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>VBY-036</keyword>
	<keyword>Maximum</keyword>
	<keyword>Pharmacodynamic</keyword>
	<keyword>Pharmacokinetic</keyword>
</DOC>